Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC.

Cancer Discov. 2012 Jun;2(6):524-39. doi: 10.1158/2159-8290.CD-11-0320. Epub 2012 Apr 23.

2.

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Feb 20;6(5):3394-408.

3.

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.

Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899. Epub 2012 Jul 1.

PMID:
22713237
4.
5.

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC.

Mol Cancer Ther. 2015 Apr;14(4):865-76. doi: 10.1158/1535-7163.MCT-14-0845. Epub 2015 Feb 11.

6.

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.

Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, Wallace E, Woessner RD, Gross S.

Cancer Biol Ther. 2011 Nov 1;12(9):788-96. doi: 10.4161/cbt.12.9.17673. Epub 2011 Nov 1.

PMID:
21892012
7.

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.

Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.

Mol Cancer Ther. 2013 Aug;12(8):1442-52. doi: 10.1158/1535-7163.MCT-13-0025. Epub 2013 May 22.

8.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE.

Clin Cancer Res. 2011 Sep 1;17(17):5638-48. doi: 10.1158/1078-0432.CCR-11-0650. Epub 2011 Jul 28.

9.

Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, Pawel B, Shumway SD, Maris JM, Cole KA.

Cancer Res. 2013 Jan 15;73(2):776-84. doi: 10.1158/0008-5472.CAN-12-2669. Epub 2012 Nov 7.

10.

Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.

Li Y, Saini P, Sriraman A, Dobbelstein M.

Oncotarget. 2015 Oct 20;6(32):32339-52. doi: 10.18632/oncotarget.5891.

11.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.

Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S.

Leukemia. 2015 Apr;29(4):807-18. doi: 10.1038/leu.2014.296. Epub 2014 Oct 6.

12.

Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.

Mak JP, Man WY, Chow JP, Ma HT, Poon RY.

Oncotarget. 2015 Aug 28;6(25):21074-84.

13.

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H.

J Clin Invest. 2012 Apr;122(4):1541-52. doi: 10.1172/JCI58765. Epub 2012 Mar 26. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702.

14.

MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.

Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S.

Mol Cancer Ther. 2012 Jan;11(1):174-82. doi: 10.1158/1535-7163.MCT-11-0529. Epub 2011 Nov 14.

15.

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.

Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H.

Mol Cancer Ther. 2009 Nov;8(11):2992-3000. doi: 10.1158/1535-7163.MCT-09-0463. Epub 2009 Nov 3.

16.

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA.

BMC Cancer. 2015 Jun 10;15:462. doi: 10.1186/s12885-015-1474-8.

17.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

18.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

19.

Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.

Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC.

Mol Cancer Ther. 2013 Dec;12(12):2675-84. doi: 10.1158/1535-7163.MCT-13-0424. Epub 2013 Oct 11.

20.

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.

Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9.

Supplemental Content

Support Center